The first day of open-protocol rollout looked nothing like a corporate launch. There was no single banner and no founder's speech. There were seven clinics, pharmacists holding version-controlled instructions, and patients worried that “open” was merely a new name for the old registry.
At Ngara clinic, the first desk handled consent before medicine. Clinical care, safety reporting and optional research appeared as separate choices. Marketing was not bundled into treatment.
“If I refuse research, can I still get K-17?” one man asked.
“Yes, if your clinician recommends it,” the pharmacist said.
“And if I refuse Nocturne access?”
“The Board can receive the minimum safety report. The company does not automatically receive your full chart.”
He signed only the clinical section.
One clinic failed its first teach-back because a staff member thought the research box was mandatory. Leila paused that site's rollout for retraining despite the waiting queue.
“Speed with bad consent rebuilds the defect we just removed,” she said.
After retraining, the first patient declined research and still received care.
Nuru arrived later and surprised Leila by choosing Westpark instead of Kioo.
“Why?” Leila asked.
“My physio is nearby. And I don't want every follow-up where you work.”
Leila almost argued. Then she remembered the recusal form.
“Westpark is licensed.”
“I checked.”
“Of course you did.”
A portable referral was created without a Nocturne membership number. Nuru chose safety reporting and Westpark clinical sharing, leaving research undecided.
At Southline, a mild K-17 reaction appeared: nausea and temporary sensory dulling. A staff member suggested keeping it internal until more cases appeared.
“Open protocol means small defects are visible too,” Leila said.
The network held a ten-minute review. The protocol added stronger pre-dose counseling and a slightly longer observation window for the relevant risk group. Version 1.2 became 1.3. The public safety page noted the mild reaction and the monitoring change without claiming perfect safety.
Later, an IT bug accidentally set research permission on three records. The team did not fix it silently. They logged the defect, removed the flags, searched for every affected record and notified all three patients.
“The new system made a mistake on day one,” a pharmacist said.
“Yes,” Leila replied. “The difference is that the mistake has a visible correction trail.”
The Board released K-17 technical specifications to three licensed manufacturers under the emergency regime, with quality controls and equivalence testing. Nocturne remained one of them, not the only one.
By the end of the day, forty-three patients had received care across different clinics. Four had moved providers. One adverse reaction had changed the protocol in public.
Nuru called from Westpark and raised her new temporary clinical ID, which carried no Nocturne logo.
“They let me choose my emergency contacts too,” she said. “Samwel first. You second.”
Leila frowned theatrically. “Second?”
“He argues less.”
“Fair.”
Nuru smiled.
Before the call ended, Nuru told Leila that Westpark had let her choose her emergency contacts instead of copying them from an old account. She had listed Samwel first and Leila second.
“Second?” Leila protested.
“He argues less.”
“Fair.”
That small choice mattered more than the slogan on any consent form. Nuru's autonomy now changed the actual flow of information. At the network level, patients were beginning to leave lifetime contracts without losing treatment continuity, and the first-day software defect had been corrected in public rather than buried.
The clinic network closed its first-day review by assigning owners to every open defect. The consent bug belonged to IT and privacy; the mild reaction belonged to the clinical monitoring team; manufacturer equivalence testing belonged to the Board laboratory group. None of those issues was allowed to disappear behind the phrase “rollout successful.”
Leila posted the next review time and left the clinics operating without her approval on every ordinary dose. That was the point of the design: qualified teams could act, while the shared rules made their actions visible.
Leila looked at the unfamiliar Westpark wall behind her sister and let the distance remain part of the success.
Leila simply nodded.
“I chose my own clinic.”